Top brokers name 3 ASX shares to buy next week 14 March 2021

Last week saw a number of broker notes hitting the wires once again. Three buy ratings that caught my eye are summarised below.

Here’s why brokers think investors ought to buy them next week:

According to a note out of Citi, its analysts have upgraded this biotech giant’s shares to a buy rating with a $310.00 price target. The broker made the move largely on valuation grounds after recent weakness in the CSL share price. Citi expects the COVID-19 vaccine rollout to support plasma collections in the coming months. In addition to this, it remains confident that demand for its core plasma-based products will be robust in the medium term. The CSL share price ended the week at $253.26.

A note out of Credit Suisse reveals that…